Skip to main content
News Icon

News categories: Publication

Heinsberg-Study Published

Bonn-based research team determine COVID-19 infection fatality ratein "Heinsberg Study"

The district of Heinsberg in the German state of North Rhine-Westphalia is considered a hot spot for the novel Coronavirus SARS-CoV-2. Following a carnival celebration, the district became one of the first areas in Germany where the pathogen spread and infected large quantities of people. As part of the study, a research team led by Prof. Dr. Hendrik Streeck and Prof. Dr. Gunther Hartmann from the University of Bonn and members of the Cluster of Excellence ImmunoSensation2 carried out a large study to precisely determine the infection fatality rate for the first time among other findings. The results of the study have been pre-published and are now presented to scientists and the public. Publication in a peer-reviewed journal is to follow.

"The results can be used to further improve models on the transmission behavior of the virus. Until now, basis for such data has been relatively uncertain," says co-author Prof. Dr. Gunther Hartmann, Director of the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn and speaker of the Cluster of Excellence, ImmunoSensation2. The study also provides important indicators for further research on SARS-CoV-2 such as: the infection risk dependent on age, gender and pre-existing conditions; the increased severity of illness amidst special circumstances of a massive infection incident such as in Gangelt, or on the risk of infection within families.


Publication

Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event Hendrik Streeck, Bianca Schulte, Beate M. Ku¨mmerer, Enrico Richter, Tobias Höller, Christine Fuhrmann, Eva Bartok, Ramona Dolscheid, Moritz Berger, Lukas Wessendorf, Monika Eschbach-Bludau, Angelika Kellings, Astrid Schwaiger, Martin Coenen, Per Hoffmann, Birgit Stoffel-Wagner, Markus M. Nöthen, Anna-Maria Eis-Hu¨binger, MartinExner, Ricarda Maria Schmithausen, Matthias Schmid and Gunther Hartmann, https://www.medrxiv.org/content/10.1101/2020.05.04.20090076v2


Contact for the media

Dr. Andreas Archut

University Communications

University of Bonn

Phone: +49 (0)228 73-7647

E-Mail: kommunikation@uni-bonn.de

Related news

The human P2X4 receptor

News categories: Publication

A starting point for the development of new pain and cancer drugs

The human P2X4 receptor plays an important role in chronic pain, inflammation and some types of cancer. Researchers at the University of Bonn and the University Hospital Bonn (UKB) have now discovered a mechanism that can inhibit this receptor. The results were recently published in the scientific journal Nature Communications and open up a pathway for the development of new drugs. A study carried out by the University of Bonn and the University Hospital Bonn throws light on how P2X2 can be inhibited. The results have recently been published in Nature Communications.
View entry
Kato research group

News categories: Publication

Ominous false alarm in the kidney

Bonn researchers have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction. In cooperation with Nanyang Technological University Singapore and the University Hospital Würzburg, among others, the study provides an explanation for how a point mutation in the immune receptor RIG-I transforms the body's defense system into a self-destructive force and causes severe organ-specific autoimmune diseases. The results have now been published in the journal Science Immunology.
View entry
News_Proebstel

News categories: Publication

Unique immune signatures to distinguish MOGAD from MS

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body’s immune system mistakenly attacks the protective myelin sheath of nerve fibers in the central nervous system. Although MOGAD induces symptoms similar to multiple sclerosis (MS), its underlying biology appears to be fundamentally different. Understanding these distinctions is crucial for developing effective, disease-specific treatments. A new international study now sheds light on these immune differences.
View entry

Back to the news overview